Exercise and GLP-1 drugs: A powerful combination for long-term health and economic gains
In a groundbreaking study, the integration of GLP-1 obesity medications with structured exercise programs has been hailed as a game-changer, offering both clinical and economic benefits. The research, conducted by FTI Consulting's Center for Healthcare Economics and Policy, in collaboration with fitness sector organizations, reveals a compelling case for policymakers to prioritize physical activity in treatment pathways.
The Economic Impact
The economic model applied across five countries paints a promising picture. In Canada, the study projects a remarkable return on investment, with a 105% ROI over 10 years, escalating to a staggering 526% and $17.9 billion over three decades. This substantial figure underscores the potential for significant cost savings and societal value.
Zach Weston, executive director of the Fitness Industry Council of Canada, emphasizes the structural challenge the country faces. Canada's rising obesity-related costs and physical inactivity rates make the case for structured exercise as a vital component of healthcare.
Clinical Advantages
The clinical benefits of combining exercise with GLP-1 therapy are equally impressive. The study highlights preserved muscle mass during weight loss, sustained strength and bone health, reduced weight regain, and lower rates of costly health events. Additionally, it addresses the reduction in medical costs and productivity losses, while enhancing patient longevity and quality of life.
A Warning and a Call to Action
However, a recent study presented at ENDO 2026 reveals a concerning trend. GLP-1 users are becoming less active post-treatment. The average daily steps and moderate-to-vigorous physical activity minutes decreased significantly, emphasizing the need for ongoing exercise during treatment.
Dr. Sajana Maharjan, study lead, underscores the importance of physical activity, especially given that GLP-1 medications reduce lean muscle mass. This finding further emphasizes the critical role of exercise in maintaining overall health.
Policy Gaps and the Way Forward
Despite the compelling evidence, Canada's public drug plans currently exclude GLP-1 medications for obesity treatment. This policy gap highlights the need for governments to recognize structured exercise, particularly strength training, as an essential component of obesity care. The Fitness Industry Council of Canada, along with other associations, is urging policymakers to establish referral pathways and track outcomes beyond weight loss.
In conclusion, the integration of exercise with GLP-1 drugs presents a powerful strategy for long-term health and economic benefits. As the fitness industry advocates for policy changes, the healthcare system must embrace this holistic approach to address the challenges of obesity and inactivity, ultimately improving the well-being of individuals and societies.
